黏膜相关淋巴组织淋巴瘤IELSG-19随机试验最终结果:利妥昔单抗联合苯丁酸氮芥较单用苯丁酸氮芥或利妥昔单抗单药改善无事件生存和无进展生存
IELSG-19是一项针对黏膜相关淋巴组织淋巴瘤初治患者的随机III期研究,比较苯丁酸氮芥单药、利妥昔单抗联合苯丁酸氮芥及利妥昔单抗单药。中位随访7.4年,联合组无事件生存和无进展生存均显著优于单药组,但5年总生存各组均约90%,未见总生存获益。所有治疗耐受良好,未记录到意外毒性。
要点
- 中位随访7.4年,利妥昔单抗联合苯丁酸氮芥较苯丁酸氮芥单药显著改善无事件生存(风险比0.54,95%CI 0.38-0.77)。
- 5年无事件生存率:苯丁酸氮芥单药51%(95%CI 42-60),利妥昔单抗单药50%(95%CI 42-59),联合组68%(95%CI 60-76),P=0.0009。
- 联合组无进展生存亦显著更优(P=0.0119),但5年总生存各组均约90%,无事件生存和无进展生存的改善未转化为总生存延长。
核心结论
- 利妥昔单抗联合苯丁酸氮芥在黏膜相关淋巴组织淋巴瘤中显示出更优疗效,但无事件生存和无进展生存的改善未转化为总生存延长。
研究设计与样本
- IELSG-19是一项随机III期研究,最初按1:1随机分配接受苯丁酸氮芥单药或苯丁酸氮芥联合利妥昔单抗。
- 计划入组252例后方案修订为三臂设计(1:1:6),新增利妥昔单抗单药组,最终样本量为454例。
- 主要终点为无事件生存,苯丁酸氮芥与联合组的分析在第三臂分析前单独进行并报告。
主要发现
- 中位随访7.4年,利妥昔单抗联合苯丁酸氮芥较苯丁酸氮芥单药显著改善无事件生存(风险比0.54,95%CI 0.38-0.77)。
- 5年无事件生存率:苯丁酸氮芥单药51%(95%CI 42-60),利妥昔单抗单药50%(95%CI 42-59),联合组68%(95%CI 60-76),P=0.0009。
- 联合组无进展生存亦显著更优(P=0.0119)。
- 5年总生存各组均约90%。
- 所有治疗耐受良好,未记录到意外毒性。
关键数值与推荐
- 苯丁酸氮芥单药方案:6 mg/m2/d口服,第1-6周、第9-10周、第13-14周、第17-18周、第21-22周。
- 利妥昔单抗联合方案:苯丁酸氮芥同上方案,联合利妥昔单抗375 mg/m2静脉注射,第1、2、3、4、9、13、17、21周的第1天。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose There is no consensus on the optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The IELSG-19 phase III study, to our knowledge, was the first such study to address the question of first-line treatment in a randomized trial. Patients and Methods Eligible patients were initially randomly assigned (1:1 ratio) to receive either chlorambucil monotherapy (6 mg/m2/d orally on weeks 1 to 6, 9 to 10, 13 to 14, 17 to 18, and 21 to 22) or a combination of chlorambucil (same schedule as above) and rituximab (375 mg/m2 intravenously on day 1 of weeks 1, 2, 3, 4, 9, 13, 17, and 21). After the planned enrollment of 252 patients, the protocol was amended to continue with a three-arm design (1:1:6 ratio), with a new arm that included rituximab alone (same schedule as the combination arm) and with a final sample size of 454 patients. The main end point was event-free survival (EFS). Analysis of chlorambucil versus the combination arm was performed and reported separately before any analysis of the third arm. Results At a median follow-up of 7.4 years, addition of rituximab to chlorambucil led to significantly better EFS (hazard ratio, 0.54; 95% CI, 0.38 to 0.77). EFS at 5 years was 51% (95% CI, 42 to 60) with chlorambucil alone, 50% (95% CI, 42 to 59) with rituximab alone, and 68% (95% CI, 60 to 76) with the combination ( P = .0009). Progression-free survival was also significantly better with the combination ( P = .0119). Five-year overall survival was approximately 90% in each arm. All treatments were well tolerated. No unexpected toxicities were recorded. Conclusion Rituximab in combination with chlorambucil demonstrated superior efficacy in mucosa-associated lymphoid tissue lymphoma; however, improvements in EFS and progression-free survival did not translate into longer overall survival.
引用
- Zucca E, Conconi A, Martinelli G, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol. 2017. PMID: 28355112. doi:10.1200/JCO.2016.70.6994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。